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Abstract
Introduction In systemic sclerosis (SSc) little evidence for the
effectiveness of anti-inflammatory and immunosuppressive
therapy exists. The objective of this study was to determine the
extent to which SSc patients are treated with corticosteroids
and immunosuppressive agents.
Methods Data on duration and dosage of corticosteroids and
on the type of immunosuppressive agent were analyzed from
1,729 patients who were registered in the German Network for
Systemic Scleroderma (DNSS).
Results A total 41.3% of all registered SSc patients was treated
with corticosteroids. Corticosteroid use was reported in 49.1%
of patients with diffuse cutaneous SSc and 31.3% of patients
with limited cutaneous SSc (P < 0.0001). Among patients with
overlap disease characteristics, 63.5% received corticosteroids
(P < 0.0001 vs. limited cutaneous SSc). A total 16.1% of the
patients received corticosteroids with a daily dose  15 mg
prednisone equivalent. Immunosuppressive therapy was
prescribed in 35.8% of patients. Again, among those patients
with overlap symptoms, a much higher proportion (64.1%) was
treated with immunosuppressive agents, compared with 46.4%
of those with diffuse cutaneous SSc sclerosis and 22.2% of
those with limited cutaneous SSc (P  < 0.0001). The most
commonly prescribed drugs were methotrexate (30.5%),
cyclophosphamide (22.2%), azathioprine (21.8%) and
(hydroxy)chloroquine (7.2%). The use of these compounds
varied significantly between medical subspecialties.
Conclusions Despite limited evidence for the effectiveness of
corticosteroids and immunosuppressive agents in SSc, these
potentially harmful drugs are frequently prescribed to patients
with all forms of SSc. Therefore, this study indicates the need to
develop and communicate adequate treatment
recommendations.
DNSS: Deutsches Netzwerk für Systemische Sklerodermie (German Network for Systemic Scleroderma); ESR: erythrocyte sedimentation rate; SSc: 
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Introduction
Systemic sclerosis (SSc) is a rare autoimmune disease involv-
ing the skin and internal organs. The disease hallmark is an
overproduction and accumulation of collagen and other extra-
cellular matrix proteins, resulting in thickening of the skin and
fibrosis of the affected organs (for example, gastrointestinal
tract, lung, heart, and kidney). The etiology of SSc is still not
fully elucidated, but the dominant phenomena are immuno-
logic mechanisms, vascular endothelial cell injury and an acti-
vation of fibroblasts.
Significant advances have been made during recent years in
symptomatic organ-specific therapy [1]. Only few controlled
clinical studies, however, have been performed for drugs with
anti-inflammatory, immunosuppressive or anti-fibrotic proper-
ties. The rarity of SSc, several disease subsets and a highly
variable course of disease are major obstacles to performing
adequately designed studies with a sufficient number of
patients [2].
Corticosteroids are still the mainstay of treatment for most
autoimmune diseases. There is no randomized controlled
study addressing the use of corticosteroids in SSc, however,
that demonstrates improvement of skin fibrosis or organ
involvement [3]. In contrast, it has been observed that high-
dose corticosteroid application ( 15 mg/day) may contribute
to the development of renal crisis [4].
Similarly, large well-controlled prospective clinical trials are
lacking for most of the drugs with immunosuppressive or anti-
fibrotic properties that have been used in the treatment of
SSc. The small number of controlled studies that were per-
formed failed to demonstrate a significant benefit – with the
exception of cyclophosphamide, which showed a modest, sta-
tistically significant benefit in a recent randomized controlled
trial [5], and to a limited extent methotrexate for early active
disease [6].
The lack of data on the frequency and extent to which SSc
patients are treated with corticosteroids or immunosuppres-
sive agents in clinical practice, few well-controlled clinical
studies and the limited effectiveness of available therapies are
probably the main obstacles for the development of clinical
recommendations or guidelines for immunosuppressive ther-
apy of SSc patients.
In October 2003, the German Network for Systemic Sclero-
derma (Deutsches Netzwerk für Systemische Sklerodermie
(DNSS)) was established to improve basic and clinical
research for this complex disease. The network, which is
funded by the German Federal Ministry of Education and
Research, consists of rheumatologists, dermatologists, pulmo-
nologists, and nephrologists, who established a nationwide
patient registry to collect data from a sufficiently high number
of patients to analyze diagnostic and therapeutic procedures.
For the present study, the registry of the network was used to
investigate the prescription of corticosteroid and immunosup-
pressive therapy in a large number of SSc patients. The study
demonstrates the widespread use of glucocorticoids and the
large variety of immunosuppressive agents used, despite the
lack of evidence for their effectiveness. This result reflects also
characteristic problems associated with the treatment of rare,
chronic autoimmune diseases in general. Both the physician
and the patient are confronted with a severe, potentially life-
threatening and difficult to treat chronic disease. Both parties,
to varying degrees, therefore feel obliged to intervene thera-
peutically, despite the lack of well-performed clinical trials and
corresponding therapeutic guidelines.
Materials and methods
The DNSS presently consists of 27 clinical centers embracing
different subspecialties; that is, rheumatology (11 centers),
dermatology (13 centers), pulmonology (two centers), and
nephrology (one center), the latter being nationally known for
their expertise in complications of pulmonary or renal involve-
ment of SSc. The patient population reflects both those cared
for by centers of expertise in scleroderma and private practi-
tioners in a variety of specialties.
The study, including an informed consent regarding data stor-
age, has been approved by the lead ethics committee of the
Cologne University Hospital and by the respective ethics com-
mittee of the centers.
By August 2007 more than 1,729 patients had been regis-
tered in the database. Patients with the diagnosis of undiffer-
entiated scleroderma and SSc sine scleroderma were
excluded from this analysis on corticosteroid and immunosup-
pressive therapy to enable comparison with other independent
populations. The analysis thus focused on a total of 1,416 reg-
istered patients, grouped into diffuse cutaneous SSc (34.7%;
492/1,416 patients), limited cutaneous SSc (53.4%; 756/
1,416 patients) and overlap subsets (11.9%; 168/1,416
patients) (Table 1).
Complete data sets on corticosteroid therapy were available
for 1,396 registered patients and data sets on immunosup-
pressive therapy for 1,394 registered patients with the diffuse
cutaneous SSc, limited cutaneous SSc and overlap subsets.
The data, which are entered in the patient registry, are col-
lected on a four-page patient registration form – which was
adopted by the Network via consensus, and which is used by
all contributing clinical centers. The patient registration form
records data on gender, date of birth, disease subsets as well
as information on organ involvement, antibodies or current
symptoms as published previously [7]. A separate page solic-
its information on drug and other therapies. Data on corticos-
teroid and immunosuppressive therapy are given as milligrams
per day. Two reference documents (that is, a set of definitionsAvailable online http://arthritis-research.com/content/11/2/R30
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for the items on the registration form, and recommendations
for organ-specific diagnostic procedures) were prepared to
ensure consistency of registered patients' data in the network
centers.
Organ involvement was defined as recently described in detail
[7]. To ensure the detection of disease heterogeneity, the reg-
istry defined five subsets – limited cutaneous SSc [8], diffuse
cutaneous SSc [8], overlap syndrome [9,10], SSc sine sclero-
derma [11-13], and undifferentiated connective tissue disease
with features of scleroderma [14,15] – as recently described
[7]. The overlap subset was defined as SSc according to
American College of Rheumatology criteria or the main symp-
toms of SSc, combined with another nonorgan-specific
autoimmune disease or with the main symptoms of such a dis-
ease and, as a rule, with proof of characteristic autoantibodies
(for example, anti-U1-RNP or anti-PMScl).
Data recording and statistical analyses
The DNSS maintains a centralized online patient registry in
which all patient data from the four-page DNSS-patient regis-
tration form are entered. A Central Office for Coordination, set
up at the Department of Dermatology and Venerology at the
University of Cologne, acts as the data manager. The DNSS
closely cooperates with the Center for Clinical Studies
Cologne (ZKS Koeln), which, on the basis of the registration
form, designed the online patient registry using the MACRO
software for Clinical Trials. Seven clinical centers currently use
the option to register their patients online. The remaining cent-
ers perform their registration on paper and send the filled-in
questionnaires to the Central Office for Coordination, where
the registration forms are validated and entered into the online
registry.
The data were statistically analyzed using Excel and SPSS
14.0 for tabular and graphic representation. Statistical evalua-
tion was performed using contingency table tests (chi-square
Table 1
Patient characteristics
Total Missing data Limited cutaneous systemic 
sclerosis
Diffuse cutaneous systemic 
sclerosis
Overlap syndrome
Characteristic
Number of patients (n (%)) 1,419 (100%) 0.9 56 (53.4%) 492 (34.7%) 168 (11.9%)
Female 82.8 0.1 88.0 74.9 85.1
Male 17.2 0.1 12.0 25.1 14.9
Antinuclear antibodies 
(ANA)-positive
91.5 0.5 89.9 91.9 95.8
Scl 70-positive 30.9 0.7 18.5 55.6 11.4
Anticentromere antibodies 
(ACA)-positive
36.6 2.5 59.7 10.2 16.2
Organ involvement by systemic sclerosis subset
Raynaud phenomenon 95.8 0.2 96.3 95.1 96.4
Skin involvement 93.5 0.4 92.8 97.5 83.9
Pulmonary hypertension 14.2 0.4 12.8 17.7 9.5
Pulmonary fibrosis 38.0 0.4 24.6 59.1 33.3
Esophagus 63.6 0.3 61.1 67.4 64.9
Stomach 15.2 0.5 15.8 14.5 14.9
Intestine 5.7 0.5 6.3 5.1 5.4
Kidney 12.3 0.5 10.3 16.1 7.1
Heart 14.9 0.5 11.2 21.2 11.3
Musculoskeletal system 51.0 8.1 45.1 53.7 68.3
Nervous system 6.2 1.8 5.7 5.6 10.1
Sicca symptoms 42.0 2.3 45.5 36.9 43.4
Masticatory organ 30.3 12.4 25.3 38.6 27.5
Data presented as percentages unless stated otherwise.Arthritis Research & Therapy    Vol 11 No 2    Hunzelmann et al.
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test or Fisher's exact t test) to describe significant differences
or associations. In general, P values < 0.05 are mentioned.
When multiple testes were performed, however, only values
below 0.0001 were considered significant. For most variables,
less than 5% of data were missing. In some sets, however, the
percentage of missing data is higher; for example, the muscu-
loskeletal system (synovitis and/or myositis based on clinical
evaluation and raised serum muscle enzyme levels, joint con-
tracture and muscle weakness), masticatory organ (microsto-
mia, obvious decreased mouth opening, fibrosis of the lingual
frenulum) and palpitations (subjective sensation of an
increased, accelerated or irregular heartbeat). This is due to
the fact that some parameters were added to the registration
form after the registry had been initiated. Patients with missing
data for the respective analysis were excluded from the
analysis.
Furthermore, multivariate logistic analyses with particular
attention to multiple collinearity were performed to assess
which factors might be associated with the use of corticoster-
oid or immunosuppressive agents. Odds ratios and the corre-
sponding 95% confidence intervals were calculated.
The evaluation focused on a comparison between the use of
different corticosteroid dosages and immunosuppressive
agents related to the following variables: SSc subset (diffuse
cutaneous SSc, limited cutaneous SSc, overlap syndrome),
antibody status (Scl-70, centromere), organ involvement (gas-
trointestinal tract, lung, heart, kidney, musculoskeletal system,
skin) as well as laboratory/clinical parameters (for example,
erythrocyte sedimentation rate (ESR), proteinuria, modified
Rodnan skin score) and medical subspecialty (that is, rheuma-
tologists, dermatologists).
Results
Corticosteroid use
Complete data sets on corticosteroid therapy were available
for 1,396 out of 1,416 patients. A total 41.3% of SSc patients
(577/1,396) received corticosteroids; 73.3% of these
patients received additional immunosuppressive therapy. The
use of corticosteroid therapy varied considerably in the differ-
ent disease subsets, with overlap syndrome displaying the
highest frequency (63.5%) (see Figure 1). Internal organ
involvement was associated with varying degrees of corticos-
teroid use. Lung fibrosis was associated with the highest fre-
quency (55.6%), followed by renal involvement (56.5%),
cardiac involvement (51.2%), musculoskeletal involvement
(47.9%), pulmonary hypertension (44.7%) and gastrointesti-
nal involvement (43.0%).
Male patients received corticosteroids more often than female
patients (52.5% (127/242) vs. 38.9% (449/1,153)) (P  <
0.0001). An ESR above 30 mm/hour resulted in more frequent
corticosteroid use (48.3%), compared with values below 30
mm/hour (40.2%) (P < 0.02). Patients with cutaneous involve-
ment alone (n = 447) received corticosteroids (27.1%) and/or
immunosuppressive agents (21.5%) to a lesser degree com-
pared with patients suffering from lung and musculoskeletal
manifestations (121/447).
Exact dosages of corticosteroid therapy were documented for
466 patients, and revealed that 16.9% (79/466) of patients
were given dosages of prednisone equivalents  15 mg/day,
28.9% (135/466) received dosages <15 mg/day and  7.5
mg/day, and 54.1% of patients (252/466) received dosages
below 7.5 mg/day. Patients with an elevated ESR constituted
a higher proportion of patients were treated with dosages
>7.5 mg/day (32.5% vs. 20.2%) (P < 0.005). Dosages <15
mg/day were significantly associated with the limited cutane-
ous SSc subset (P < 0.009), whereas dosages  15 mg/day
were associated with the overlap syndrome (P < 0.03).
Since corticosteroids have been described as a risk factor for
renal involvement and for renal crisis, we analyzed the fre-
quency of corticosteroid use in patients with proteinuria
(42.9%; 60/140), hypertension (44.1%; 138/313) or renal
insufficiency (47.7%; 95/199). In the majority of patients, renal
insufficiency was not due to renal crisis (unpublished observa-
tion). Multivariate analysis (Table 2) showed that kidney
involvement was indeed associated with corticosteroid use.
During the observation period, however, there was no statisti-
cally significant difference in kidney involvement between the
two different corticosteroid dosage groups (<15 mg vs.  15
mg).
Corticosteroids were prescribed significantly more often by
rheumatologists (48.3%; 360/746) than by dermatologists
(33.4%; 217/650) (P < 0.0001) (Table 3). This difference
cannot be ascribed to disease severity since no significant dif-
ferences were found in organ involvement in the two patient
Figure 1
Use of corticosteroids in systemic sclerosis subtypes Use of corticosteroids in systemic sclerosis subtypes. dcSSc, diffuse 
cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic 
sclerosis.Available online http://arthritis-research.com/content/11/2/R30
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groups other than musculoskeletal involvement or sicca symp-
toms. Multivariate logistic analysis accounting for differences
in subset frequency and organ involvement confirmed this
observation (Table 2).
Immunosuppressive agents
In the study population, 35.8% (499/1,394) of patients were
treated with immunosuppressive agents. Patients suffering
from the diffuse type of SSc received immunosuppressive
drugs more often (46.4%; 225/485) than individuals with lim-
ited cutaneous SSc (22.2%; 165/742) (P < 0.0001) (see Fig-
ure 2).
Male patients (46.9%; 113/241) were more frequently treated
with these drugs than female patients (33.4%; 385/1,152) (P
Table 2
Multivariate relationship of corticosteroid and immunosuppressive agent use with subspecialty, disease subset and organ 
involvement
Variable Corticosteroid therapy vs. no corticosteroid therapy Immunosuppressive therapy vs. no immunosuppressive 
therapy
Odds ratio 95% confidence interval P value Odds ratio 95% confidence interval P value
Subspecialties 
(rheumatology vs. 
dermatology)
1.54 1.19 to 1.98 0.001 2.46 1.88 to 3.21 <0.0001
Gender (female vs. male) 0.69 0.51 to 0.96 0.025 0.78 0.56 to 1.10 0.13
Age (years) 0.99 0.99 to 1.01 0.67 0.99 0.98 to 1.00 0.04
Systemic sclerosis subsets
Limited cutaneous 
systemic sclerosis 
(reference group)
1.00 1.00
Diffuse cutaneous 
systemic sclerosis
1.47 0.45 to 4.88 0.53 1.77 0.51 to 6.19 0.37
Overlap syndrome 3.64 1.06 to 12.51 0.04 3.69 1.02 to 13.37 0.05
Organ involvement
Pulmonary hypertension 0.83 0.59 to 1.17 0.30 0.94 0.66 to 1.35 0.73
Pulmonary fibrosis 2.30 1.77 to 2.99 <0.0001 1.53 1.16 to 2.00 0.002
Musculoskeletal system 1.40 1.08 to 1.81 0.01 1.31 1.00 to 1.71 0.05
Esophagus 1.01 0.78 to 1.29 0.96 0.92 0.70 to 1.20 0.53
Kidney 1.66 1.12 to 2.47 0.01 0.91 0.59 to 1.38 0.64
Heart 1.28 0.91 to 1.81 0.16 1.34 0.93 to 1.92 0.12
Table 3
Differences between corticosteroid and immunosuppressive therapy use between rheumatological and dermatological centers of 
the DNSS
Treatment Rheumatological centers (%) Dermatological centers (%) P value
Corticosteroids 48.3 (360/746) 33.4 (217/650) <0.0001
Immunosuppressants 45.6 (340/745) 24.5 (159/649) <0.0001
Cyclophosphamide 21.5 (73/340) 23.9 (38/159)
Azathioprine 21.8 (74/340) 22.0 (35/159)
Methotrexate 35.9 (122/340) 18.9 (30/159) <0.0001
(Hydroxy)chloroquine 8.8 (30/340) 3.8 (6/159) <0.04
DNSS, Deutsches Netzwerk für Systemische Sklerodermie (German Network for Systemic Scleroderma).Arthritis Research & Therapy    Vol 11 No 2    Hunzelmann et al.
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< 0.0001). The frequency of organ involvement associated
with the use of immunosuppressive agents varied considera-
bly. Lung fibrosis was associated with the highest frequency
(44.4%; 236/531), followed by cardiac involvement (44.7%;
92/206), musculoskeletal involvement (43.4%; 285/657), pul-
monary hypertension (40.1%; 79/197), renal involvement
(38.7%; 65/168) and gastrointestinal involvement (36.7%;
327/891). Elevation of the ESR above 30 mm/hour was also
associated with an increased use of these agents (44.6%
(119/267) vs. 34.9% (337/965)) (P < 0.004). Patients with
cutaneous involvement alone (n = 447) received corticoster-
oids (27.1%) and/or immunosuppressive agents (21.5%) to a
lesser degree compared with patients suffering from lung and
musculoskeletal manifestations.
The immunosuppressive agents used, in order of decreasing
frequency, are methotrexate (30.5%; 152/499), cyclophos-
phamide (22.2%; 111/499), azathioprine (21.8%; 109/499),
(hydroxy)chloroquine (7.2%; 36/499) and mycophenolate
mofetil (7.6%; 38/499). Cyclosporine A (3%; 15/499) and D-
penicillamine (3.2%; 16/499) were prescribed only on rare
occasions (Table 4). The use of the different immunosuppres-
sive agents in disease subsets is shown in Figure 3. Combina-
tion therapy with corticosteroids was frequent on average in
65.7% of patients, with no significant difference in frequency
between the various immunosuppressive agents used (Table
4).
The relative frequency of the immunosuppressive agents used
in the different subsets is shown in Figure 3. In the diffuse sub-
set the probability of the use of cyclophosphamide was signif-
icantly higher and the use of (hydroxy)chloroquine significantly
lower when compared with other immunosuppressants,
whereas in the limited subset the probability to be treated with
cyclophosphamide was significantly reduced.
No alterations in prescription frequencies for immunosuppres-
sive agents were found when the first 850 patients were com-
pared with patients 850 to 1,700 (data not shown). Significant
differences were noted, however, when prescription frequen-
cies were compared between rheumatologists and dermatol-
ogists for the use of methotrexate, mycophenolate mofetil and,
to a lesser degree, for (hydroxy)chloroquine (Table 3).
Figure 2
Use of immunosuppressive agents in systemic sclerosis subtypes Use of immunosuppressive agents in systemic sclerosis subtypes. 
dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous 
systemic sclerosis.
Figure 3
Use of different immunosuppressive agents in systemic sclerosis subtypes Use of different immunosuppressive agents in systemic sclerosis subtypes. dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous 
systemic sclerosis.Available online http://arthritis-research.com/content/11/2/R30
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Discussion
For most rare diseases there is a lack of therapeutic recom-
mendations or guidelines, owing to the poor database, the dif-
ficulty to perform clinical studies with sufficient statistical
power and an often marked clinical heterogeneity in these
patients.
SSc was therefore chosen as a paradigm to investigate the
use of corticosteroid therapy and immunosuppressive therapy
in a rare, severe disease with limited evidence for its efficacy
and an absence of validated recommendations or guidelines.
To this end, treatment was analyzed in patients whose data
were recorded in the registry of the DNSS. The patient popu-
lation comprises patients of the clinical centers specializing in
the care of SSc patients participating in the network, but also
of patients who are seen only once a year in a clinical center
participating in the network and otherwise receive care from a
rheumatologist, a dermatologist or a general practitioner in pri-
vate practice.
Corticosteroids are still a mainstay of treatment in most
autoimmune rheumatic conditions. The use of corticosteroids
in SSc is controversial as steroids inhibit proteases that
increase connective tissue turnover, thus counteracting fibro-
sis [16]. More importantly, high-dose prednisone therapy has
been associated in a retrospective case–control study with an
increased risk of developing renal crisis [4,17], a severe com-
plication of kidney involvement. No well-controlled study on
the use of corticosteroids in SSc has been published to date.
Nevertheless, experts share the opinion that glucocorticoids
may be indicated in patients with inflammatory myositis, peri-
carditis, or alveolitis [1].
Our cross-sectional study reveals that SSc patients who suffer
from diffuse skin affection or from overlap syndrome are
treated more frequently with corticosteroids than patients with
other SSc subsets. Corticosteroid use was not restricted to
patients with clear signs of inflammation, however – such as,
for example, elevated ESR, myositis, or synovitis.
Notably, a significant proportion of those individuals who
received corticosteroids were already affected by renal dys-
function. About one-sixth of the patients who were treated with
corticosteroids received prednisone doses  7.5 mg/day. This
is an unexpected result, as higher doses of glucocorticoids
have been suggested to play a role in facilitating acute renal
failure [4,17]. The frequency of renal crisis was not assessed
in the DNSS registry, and therefore no comparative data on
patients affected by renal crisis can be provided. No signifi-
cant difference in kidney involvement (that is, renal insuffi-
ciency, proteinuria) between the different corticosteroid
dosage groups was evident in our study, however, which may
be due to the relatively low number of patients in the high-dose
group.
Having evaluated the overall use of immunosuppressive
agents, we analyzed the frequency with which different com-
pounds were used. The most commonly prescribed immuno-
suppressive drug in this study, especially for patients with
overlap syndrome, was methotrexate. Methotrexate is a stand-
ard disease-modifying drug in rheumatoid arthritis, but so far
results on its use in the treatment of SSc are still contradictory.
The initially promising results with ameliorated skin score and
ESR in early diffuse disease [6] were not confirmed by a fol-
low-up study, in which neither the treatment group nor the con-
trol group experienced significant improvement during 1 year
of treatment [18]. The high frequency of methotrexate pre-
scription could reflect an increased use in patients with over-
lap syndrome presenting with signs of myositis or arthritis.
Multivariate analysis accounting for these factors, however,
failed to demonstrate a significantly increased use in these
patients.
Azathioprine, originally introduced in transplantation medicine
in the 1960s, is still widely used as corticosteroid-sparing
Table 4
Frequency of use of immunosuppressive agents and combination with corticosteroids
Immunosuppressive agent Combination with corticosteroids
Total number % Total number %
Methotrexate (152/499) 30.5 (101/152) 66.4
Cyclophosphamide (111/499) 22.2 (81/111) 73.0
Azathioprine (109/499) 21.8 (75/109) 68.8
(Hydroxy)chloroquine (36/499) 7.2 (20/36) 55.6
Mycophenolate mofetil (38/499) 7.6 (26/38) 68.4
Cyclosporine (15/499) 3.0 (9/15) 60.0
D-Penicillamine (16/499) 3.2 (7/16) 43.8Arthritis Research & Therapy    Vol 11 No 2    Hunzelmann et al.
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agent in autoimmune diseases such as systemic lupus ery-
thematosus, multiple sclerosis or bullous diseases of the skin.
A randomized placebo-controlled clinical trial on axathioprine
use in SSc is still lacking, however, while a recent uncontrolled
study described its inferiority to cyclophosphamide [19].
Although there are no data supporting the use of azathioprine,
the drug was therefore second in our study among the immu-
nosuppressive agents prescribed.
Cyclophosphamide is frequently used as immunosuppressive
drug in rheumatic diseases, such as Wegener's disease or
systemic lupus erythematosus. With an oral daily dose
between 1 and 2.5 mg/kg/day and together with prednisone,
cyclophosphamide was able to improve pulmonary function
and to increase survival in fibrosing alveolitis [3,20]. A pla-
cebo-controlled, randomized clinical trial recently confirmed
these studies [5]. Despite such proof for a disease-modifying
effect, cyclophosphamide is only ranked third in the frequency
of immunosuppressive agents used. It was, however, the sig-
nificantly most frequently used drug in the subset associated
with the most severe disease course (that is, diffuse cutane-
ous SSc).
No studies are available on the effectiveness of (hydroxy)chlo-
roquine – a drug largely used for skin involvement in lupus ery-
thematosus or in mild cases of rheumatoid arthritis – in SSc.
The reasons for use of cyclophosphamide and the preferred
use in limited cutaneous SSc can therefore only be specu-
lated, as no increased association was found for the presence
of synovitis (data not shown) or in patients with overlap
syndrome.
Mycophenolate mofetil, increasingly applied for the treatment
of allograft rejection and kidney involvement in systemic lupus
erythematosus, is used in a considerable number of patients in
our study, preferably by dermatologists, despite the poor data
on its effectiveness [21].
In uncontrolled studies, D-penicillamine was initially observed
to have a positive effect on skin thickness, which was not con-
firmed by a double-blind randomized trial [22]. This lack of
effectiveness and the considerable side effects of D-penicilla-
mine presumably have led to its low frequency of use.
The high rate of side effects caused by cyclosporine, which, in
addition, has repeatedly been reported to induce renal crisis in
SSc patients [23], can also explain the low frequency of
cyclosporine use we found in our study.
To identify possible differences in prescription habits between
medical subspecialties, we stratified our data and compared
prescription preferences in rheumatological and dermatologi-
cal centers. Rheumatologists care more frequently for patients
with overlap syndrome (P < 0.01, data not shown), which is
usually characterized by prominent musculoskeletal involve-
ment. Multivariate analysis, however, revealed that rheumatol-
ogists have a significantly higher preference for the use of
corticosteroids and immunosuppressive agents in SSc
patients, even after correction for the disease subset, muscu-
loskeletal involvement or lung fibrosis as instances associated
with increased inflammatory activity and the necessity for
immunosuppressive treatment. In the absence of therapeutic
guidelines, we assume that the different medical subspecial-
ties are guided by current daily practice, relevant knowledge
and therapeutic experience (that is, the use of methotrexate,
azathioprine, (hydroxy)chloroquine) with disease-modifying
therapy in other rheumatological diseases when deciding on
an anti-inflammatory therapy in a severe autoimmune disease
such as SSc.
Our findings are consistent with those of Pope and colleagues
[24], who surveyed the therapeutic practice and the use of
immunosuppressive agents and corticosteroids by members
of the SSc clinical trials consortium, the Canadian Rheumatol-
ogy Association and the American College of Rheumatology,
with the exception of higher rates of D-penicillamine use in
SSc in North America (that is, 20% for skin involvement).
Conclusion
The present study is the first investigating the use of corticos-
teroids and immunosuppressive therapy in a large, well-
defined cohort of SSc patients. The study reveals a wide-
spread use of anti-inflammatory and immunosuppressive ther-
apy of SSc patients in clinical practice and a marked
therapeutic difference between disease subsets. The fre-
quency with which these drugs are prescribed is in contrast to
the weak data supporting their use, or which even argue
against their use, as it is the case for higher doses of corticos-
teroids. Our analyses also suggest that, presumably due to the
lack of treatment recommendations, specialists who care for
SSc patients are guided by current treatment practices for
other autoimmune diseases when deciding for or against a
therapeutic option. The present study therefore underlines the
urgent need to develop treatment recommendations for SSc.
Specifically, these recommendations need to address the use
of corticosteroids and immunosuppressive agents with
respect to disease subsets, organ involvement and disease
activity.
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